NYSE:ABT - Abbott Laboratories Stock Price, Price Target & More

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories announced a quarterly dividend on Friday, June 8th. Shareholders of record on Friday, July 13th will be given a dividend of $0.28 per share on Wednesday, August 15th. This represents a $1.12 annualized dividend and a yield of 1.78%. The ex-dividend date of this dividend is Thursday, July 12th. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) issued its quarterly earnings results on Wednesday, April, 18th. The healthcare product maker reported $0.59 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.58 by $0.01. The healthcare product maker earned $7.39 billion during the quarter, compared to the consensus estimate of $7.28 billion. Abbott Laboratories had a net margin of 1.67% and a return on equity of 14.54%. The company's revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.48 earnings per share. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, July, 18th 2018. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories updated its FY18 earnings guidance on Wednesday, April, 18th. The company provided EPS guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus estimate of $2.86. Abbott Laboratories also updated its Q2 guidance to $0.70-0.72 EPS.

18 equities research analysts have issued 1 year target prices for Abbott Laboratories' stock. Their predictions range from $64.00 to $80.00. On average, they anticipate Abbott Laboratories' share price to reach $69.50 in the next twelve months. This suggests a possible upside of 10.2% from the stock's current price. View Analyst Ratings for Abbott Laboratories.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

News headlines about ABT stock have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Abbott Laboratories earned a news impact score of 0.13 on Accern's scale. They also gave media coverage about the healthcare product maker an impact score of 47.06 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Abbott Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include Swedbank (0.09%), Atalanta Sosnoff Capital LLC (0.06%), Gateway Investment Advisers LLC (0.06%), Gulf International Bank UK Ltd (0.03%), Park National Corp OH (0.03%) and Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Palo Capital Inc., Mckinley Capital Management LLC Delaware, Gateway Investment Advisers LLC, First Financial Bank Trust Division, Park National Corp OH, CENTRAL TRUST Co, Rockland Trust Co. and First National Bank of Omaha. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was acquired by a variety of institutional investors in the last quarter, including Swedbank, Atalanta Sosnoff Capital LLC, Dalton Greiner Hartman Maher & Co., Contravisory Investment Management Inc., State of Alaska Department of Revenue, IFM Investors Pty Ltd, YHB Investment Advisors Inc. and Bremer Trust National Association. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Daniel J Starks, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $63.06.

Abbott Laboratories has a market capitalization of $110.56 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.